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Abstract
Background: Emerging reports suggest resistance, increased tumor invasiveness and metastasis arising from 
treatment with drugs targeting vascular endothelial growth factor (VEGF). It is believed that increased tumoral hypoxia 
plays a prominent role in the development of these phenomena. Inhibition of tumoral hypoxia inducible factor (HIF-
1α) is thus becoming an increasingly attractive therapeutic target in the treatment of cancer. We hypothesized that the 
anti-VEGF effect of albendazole (ABZ) could be mediated through inhibition of tumoral HIF-1α.
Method: In vitro, the effects of ABZ on HIF-1α levels in human ovarian cancer cells (OVCAR-3) were investigated using 
hypoxic chamber or desferrioxamine (DFO) induced-hypoxia. In vivo, the effects of ABZ (150 mg/kg, i.p., single dose) on 
the tumor levels of HIF-1α and VEGF protein and mRNA were investigated by western blotting, RT-PCR and real time-
PCR.
Results: In vitro, ABZ inhibited cellular HIF-1α protein accumulation resulting from placement of cells under hypoxic 
chamber or exposure to DFO. In vivo, tumors excised from vehicle treated mice showed high levels of both HIF-1α and 
VEGF. Whereas, tumoral HIF-1α and VEGF protein levels were highly suppressed in ABZ treated mice. Tumoral 
VEGFmRNA (but not HIF-1αmRNA) was also found to be highly suppressed by ABZ.
Conclusion: These results demonstrate for the first time the effects of an acute dose of ABZ in profoundly suppressing 
both HIF-1α and VEGF within the tumor. This dual inhibition may provide additional value in inhibiting angiogenesis 
and be at least partially effective in inhibiting tumoral HIF-1α surge, tumor invasiveness and metastasis.
Background
Amongst the vast array of proangiogenic molecules iden-
tified, VEGF has been shown to play a pivotal role in
tumor angiogenesis. VEGF is a potent stimulator of
endothelial cell survival, mitogenesis, migration and dif-
ferentiation [1,2]. Angiogenesis inhibitors targeting
VEGF have shown anticancer activity in preclinical and
clinical trials. Several VEGF inhibitors have been
approved by the US Food and Drug administration for the
treatment of tumors or age-related macular degeneration
[3,4]. However, recently emerging reports suggest that the
effects of these drugs in cancer are only transitory, not
producing enduring efficacy in terms of either tumor
shrinkage or dormancy or long term survival, thus result-
ing in eventual drug resistance, vascular recovery and
relapse to progressive tumor growth [5-7]. A number of
contributing mechanisms have been proposed including
up-regulation of fibroblast growth factor (FGF), matrix
metalloproteinases (MMPs) and the induction of HIF-1α
[6,8]. The most important mediator identified to date of
the cell's response to reduced oxygen availability, HIF-1α
is preserved and activated in response to reduced oxygen
availability [9]. By affecting the expression of a wide array
of genes, HIF-1α plays a central role in angiogenesis and
in regulating the adaptation and survival of tumors
[10,11]. Perhaps to some extent this is because transcrip-
tional regulation of VEGF is critically dependent on HIF-
1α. Results from several studies have provided compel-
ling evidence that hypoxia-triggered up-regulation of
other proangiogenic factors in the presence of anti-VEGF
agents can restimulate tumor angiogenesis through
VEGF-dependent or VEGF independent pathways
[6,12,13]. More importantly, HIF-1α induction by
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hypoxia has been associated with the emergence of a
more aggressive tumor phenotype [14]. On this basis,
drugs that inhibit VEGF and angiogenesis through the
inhibition of HIF-1α may provide therapeutic benefit
over those which target the VEGF or its signaling path-
way only.
Albendazole, methyl 5-propylthio-1H-benzimidazole-
2-yl carbamate, is a benzimidazole carbamate originally
developed as a veterinary product back in 1975 and
despite its extensive use in man and farm animals, few
adverse events have been associated with its use [15,16].
Its anthelmintic action has been attributed to binding to
the helminth β-tubulin, leading to depolymerization, cell
cycle arrest and death [17,18]. Because of their interac-
tion with the microtubules, in recent years, benzimida-
zole carbamates such as albendazole and mebendazole
have been under investigation as anticancer agents. Cell
culture and animal studies utilizing human cancer cells
have revealed that both these agents are potent inducers
of apoptosis and inhibitors of tumor growth [19-23].
More recently, using an experimental model of ovarian
cancer with malignant ascites formation, we demon-
strated that, chronic treatment with ABZ leads to sup-
pression of VEGF levels, inhibition of malignant ascites
formation and arrest of tumor growth [24,25]. In the cur-
rent study we sought to investigate if the observed ABZ
anti-VEGF effect is mediated through the inhibition of
the HIF pathway. Herein, we report that, in vitro experi-
ments performed using hypoxic chamber and DFO, pro-
vided evidence for the anti-HIF-1α activity of ABZ. Then,
study of the effects of a single dose of ABZ on tumoral
HIF-1α and VEGF expression revealed profound suppres-
sion of both HIF-1α and VEGF protein levels. Thus,
results from this study demonstrate that ABZ is a potent




Unless otherwise stated, all drugs and chemicals used in
this study were obtained from Sigma-Aldrich (Australian
subsidiary, Sydney). The following primary antibodies
were used through out this study: HIF-1α (H-206) rabbit
polyclonal IgG (Santa Cruz Biotechnology), VEGF (C-1)
mouse monoclonal IgG (Santa Cruz Biotechnology, Syd-
ney, Australia.), Monoclonal anti-β-actin (Sigma-
Aldrich). Secondary antibodies were goat anti rabbit IgG
HRP (Santa Cruz Biotechnology) and anti mouse IgG
peroxidase (Sigma-Aldrich).
Cell culture
The human ovarian cancer cells (OVCAR-3), originally
obtained from the American Type Culture Collection
(A T CC) were prepared for in vitro and in vivo growth
experiments as previously described [24]. Cells were
maintained in RPMI 1640 medium with 2 mM l-glu-
tamine, 2 g/L sodium bicarbonate, 4.5 g/L glucose, 10
mM HEPES, 1 mM sodium pyruvate, 0.01 mg/mL bovine
insulin, supplemented with 100 units/mL penicillin and
100 units/mL streptomycin and 10% FBS in a humidified
atmosphere at 37°C.
In vitro hypoxia tests
OVCAR-3 cells (3 × 106) seeded in 75 cm2 flasks were
grown for 72 h at 37°C to 80% confluency. Cells were
treated with ABZ (0 -1 μM) before being placed in a
sealed modular hypoxic chamber (Billups-Rothenburg,
Del Mar, CA) flushed with 1% O2, 5% CO2 and 94% N2.
The chamber was then placed in an incubator at 37°C for
4 h. For induction of chemical hypoxia, the same proce-
dure was used, except that instead of placement in
hypoxic chamber, cells were treated with the chemical
hypoxic agent desferrioxamine (DFO, 100 μM) for 4 h.
DFO is a well established hypoxymimetic agent [26]. Cells
not exposed to hypoxia or DFO were run in parallel as
controls. Following treatment, cells were washed with
PBS and scraped into RIPA buffer (300 μL). Lysates were
centrifuged (8000 rpm, 4°C, 10 min) and stored at -80°C
for analysis. HIF-1α and VEGF protein expressions were
determined by western blot analysis, while RT-PCR and
real time PCR were used to determine mRNA levels.
Establishment of i.p. xenograft
Intraperitoneal tumors were grown in 6 week old female
nude athymic Balb C nu/nu mice (Animal Resources
Centre, Perth, Western Australia). Each mouse was
injected i.p. with 10 million OVCAR-3 cells suspended in
1 mL of the medium. Animals were housed under com-
plete aseptic conditions, fed autoclaved pellets and sterile
water ad libitum. Health status of each animal was moni-
tored daily and all animal procedures were conducted in
conformity with institutional animal ethics committee
guidelines (University of New South Wales, Sydney, Aus-
tralia).
Drug treatment
Three weeks post cell inoculation, animals were ran-
domly assigned to one of the 6 treatment groups (6 mice/
group). Before proceeding with drug treatment, animals
were subjected to peritoneal lavage (2 mL of sterile nor-
mal saline injected i.p. and aspirated immediately after
kneading). Mice were then immediately treated i.p. (1
mL/20 g body weight) with either the vehicle [0.5% w/v
hydroperoxymethyl cellulose (HPMC)] or ABZ (150 mg/
kg suspended in HPMC) followed by euthanasia at the
predetermined time. Group 1 animals were euthanized
immediately after vehicle treatment. Groups 2-6 were
treated with ABZ and euthanized at 1, 6, 24, 48 or 72 hPourgholami et al. BMC Cancer 2010, 10:143
http://www.biomedcentral.com/1471-2407/10/143
Page 3 of 7
post injection respectively. Following euthanasia, perito-
n e a l  c a v i t y  w a s  w a s h e d ,  t u m o r s  w e r e  e x c i s e d ,  r a p i d l y
snap frozen in liquid nitrogen and stored at -80°C for sub-
sequent analysis. Tumors were analysed for the expres-
sion of VEGF and HIF-1 protein and mRNA.
Western blot analysis
Equivalent amounts of whole cell extracts (or tumor pro-
tein) were resolved in SDS PAGE (10% for HIF-1α and
12% for VEGF) and transferred to a PVDF membrane.
The membrane was blocked in 5% non-fat dry milk in
TBST and incubated (2 h) with indicated primary anti-
bodies (HIF-1α and VEGF, 1:200), followed by incubation
(1 h) with secondary anti body, goat anti-rabbit (1:5000)
or anti-mouse secondary antibody (1:160,000) (Sigma-
Aldrich;) for HIF-1α and VEGF respectively. Immunore-
activity was visualised by enhanced chemiluminescence
reagent (Perkin Elmer Cetus, Foster City, CA, USA). To
demonstrate equal loading, blots were stripped and rep-
robed with a specific antibody recognizing β-actin
(1:5000 dilution; Sigma-Aldrich).
Determination of mRNA by RT-PCR
Mice tumor extracts were examined for the expression of
VEGF and HIF-1α mRNA by reverse transcription-PCR.
Total RNA was isolated from the cells using the highly
pure RNA isolation kit according to the protocol pro-
vided by the manufacturer (Invitrogen, Sydney, Austra-
lia). Primers for the amplification of VEGF and HIF-1α
were constructed based on the following sequence: VEGF
sense: 5,-CAC ATA GGA GAG ATG AGC TTC-3; VEGF
anti-sense: 5,-CCG CCT CGG CTT GTC ACA T-3. The
primer amplifies the various VEGF isoforms (121 to 206).
HIF-1α sense primer 5,-TCA AAG TCG GAC AGC CTC
A-3, HIF-1α anti-sense: 5,-CCC TGC AGT AGG TTT
CTG CT-3 product for 460 bp,. The β-actin gene was
used as an internal control (202 bp; β-actin sense: 5'-CTT
CCT GGG CAT GGA GTC CT-3'; β-Actin anti-sense: 5'-
GGA GCA ATG ATC TTG ATC TT-3'). Total RNA was
used to amplify HIF-1α/VEGF/β-actin using the Super-
script TM One Step RT-PCR with Platinum®Taq (Invitro-
gen, Sydney, Australia). The amplification was carried out
using a Palm Cycler after an initial cDNA synthesis at
54°C for 30 min and 5 min at 94°C for denaturation. This
was followed by 27 cycles of denaturation at 94°C for 1
min, primer annealing at 60°C for 1 min, primer exten-
sion at 72°C for 45 s and a final extension of 72°C for 10
min. The RT -PCR products were visualized by electro-
phoresis (45 min at 100 V) on 1.5% agarose gel in 1 × TAE
buffer containing ethidium bromide.
Determination of mRNA by Real-Time PCR
To quantify mRNA levels, real-time RT-PCR (qRT-PCR)
was used. Briefly, RNA was isolated as described above
using TRIzol reagent. cDNA synthesis was performed on
RNA (1 μg) using Super Script III First - Strand Synthesis
Super Mix kit (Invitrogen Life Technologies). Real time
was performed in a Roter Gene 3000 (Corbett Life Sci-
ence, Mortlake, Australia) using SYBR Green ER qPCR
Super Mix Universal kit (Invitrogen life technologies) as
per supplier protocol. Primers used to amplify specific
gene products were GAPDH Sense 5'GCG CTG AGT
ACG TCG TGG AG 3' GAPDH Antisense 5'CAG TTG
GTG GTG CAG GAG GAG G-3'; HIF-1α Sense 5'-CCA
GTT ACG TTC CTT CGA TCA GT-3'; Anti sense 5'-
TTT GAG GAC TTG CGC TTT CA-3'. Amplification
r e a c t i o n  u s e d  f o r  H I F - 1  w e r e  p e r f o r m e d  a s  p r e v i o u s l y
described [27]. Data obtained are expressed as CT which
is the PCR cycle number at which the accumulated fluo-
rescent signal in each reaction crosses a threshold above
background. The relative expression levels were calcu-
lated relative to the control using the comparative Ct
(ΔΔCt) method where the relative expression is calcu-
lated as 2-ΔΔCt.
Statistical analysis
GraphPad Prism version 5.0 was used for data analysis.
All data are reported as the mean ± s.e.m. In vitro data
were analysed using Student's t test followed by Tukeys.
Animal data were analysed using Mann-Whitney U test.
Effects were considered to be statistically significant at p
< 0.05.
Results
ABZ does not affect HIF-1α under normoxic conditions
We first examined the effect of ABZ on HIF-1α under
normoxic cell culture conditions. Here, OVCAR-3 cells
grown in culture were treated with ABZ (0.1-1 μM) for 4
h and then examined for the expression of HIF-1α pro-
tein. The cells did not express measurable quantity of
HIF-1α protein under normoxic conditions and their
treatment with ABZ had no affect on HIF-1α protein
expression (Figure 1A).
ABZ treatment inhibits hypoxia-induced accumulation of 
HIF-1α protein in vitro
We next examined the effect of ABZ on hypoxia-induced
HIF-1α accumulation in vitro. ABZ treated cells placed in
hypoxic chamber for 4 h were analysed for the expression
of HIF-1α. Hypoxic conditions led to dramatic increase in
HIF-1α levels while, pre-treatment of cells with ABZ
inhibited HIF-1α accumulation in a dose-dependent
manner (Figure 1B). Under these conditions, and com-
pared to vehicle treated cells, the HIF-1α levels were
reduced by 41% (p < 0.05) and 79% (p < 0.001) in 0.1 and 1
μM ABZ treated cells respectively.
Utilizing DFO, chemically induced hypoxia was used to
obtain further evidence on the in vitro effect of ABZ onPourgholami et al. BMC Cancer 2010, 10:143
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cellular HIF-1α expression. Exposure of cells to the
hypoxia mimetic agent DFO, led to 3 fold increase in
HIF-1α protein expression. Pre-treatment of cells with
ABZ led to concentration-dependent reduction in HIF-
1α levels (Figure 1C). Compared to vehicle treated con-
trols, HIF-1α protein content in cells exposed to the 1 μM
ABZ were profoundly reduced (p < 0.001).
ABZ treatment diminishes tumoral HIF-1α expression
In order to determine if these in vitro observations do
translate into in vivo anti-HIF effects, tumor bearing mice
were given a single dose of ABZ and their tumors were
excised at various time-points post drug administration.
Using western blot analysis, HIF-1α levels in these
tumors were then assessed. As shown in Figure 2A,
tumoral HIF-1α protein levels were highly reduced for up
to 48 h post ABZ administration. Peak ABZ anti-HIF-1α
effect was found to be in tumors harvested at 24 h post
drug administration. To find out if the HIF-1α suppres-
sion was a biological consequence of HIF-1mRNA inhibi-
tion by ABZ, using RT-PCR, the tumor samples were
examined for HIF-1mRNA expression. Except for the 24
h treated tumors, no reduction in HIF-1mRNA could be
detected (Figure 2B). To verify this, the 24 h tumor sam-
ples were further analysed by real-time PCR. Results
obtained show no difference in tumoral HIF-1mRNA
expression between the vehicle and ABZ treated groups
(Figure 2C).
ABZ inhibits tumoral accumulation of VEGF protein and 
mRNA
VEGF expression is tightly controlled by HIF-1α, thus a
reduction in HIF-1α expression should be directly
reflected in VEGF expression. We therefore examined the
tumor tissues for the expression of VEGF. As depicted in
Figure 3A, VEGF is highly expressed in these tumors and
treatment with a single dose of ABZ led to dramatic and
time-dependant decline on tumoral VEGF levels. This
effect paralleled the time-dependent suppression of HIF-
1α with the ABZ effect peaking during the 24-48 h post
Figure 1 Effect of ABZ on HIF-1α expression in vitro. Albendazole inhibits in vitro HIF-1α protein expression induced by hypoxia. OVCAR-3 cells 
incubated with increasing concentrations of ABZ were either kept under normoxic conditions (A) or were transferred to hypoxic chambers for 4 h (B). 
At the end of the experiment, whole cell extracts were examined for the expression of HIF-1α protein. Similarly, cells treated with ABZ were incubated 
under cell culture conditions with 100 μM hypoxia-inducing agent desferrioxamine (DFO) for 4 h (C). Each experiment was repeated at least twice. 
Values (mean ± s.e.m) were normalized to β-actin and the control vehicle treated cells.Pourgholami et al. BMC Cancer 2010, 10:143
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drug administration period (in 24 and 48 h samples p <
0.001 compared to zero time controls). To confirm that
the ABZ effect on the VEGF levels resulted from inhibi-
tion of transcriptional activity, tumoral VEGFmRNA lev-
els were examined by RT-PCR. As illustrated in Figure
3B, VEGFmRNA levels were highly suppressed in the 24
and 48 h tumor samples. These results provide strong
evidence in support of anti-HIF activity of ABZ in vivo
and hence reveal the mechanism behind its potent anti-
VEGF effects.
Discussion
Chronic ABZ treatment has recently been shown to pro-
duce antitumor and anti-VEGF effects. The results from
the present study reveal that ABZ inhibits HIF-1α accu-
mulation and VEGF production after acute administra-
tion. We examined the effects of ABZ on HIF-1α levels in
cell culture under both normoxic and hypoxic conditions.
Although the HIF-1α gene is constitutively transcribed,
under normoxic conditions HIF-1α protein is virtually
undetectable due to its oxygen-dependent degradation by
the propyl hydroxylases [28]. However, exposure to
hypoxia stops HIF-1α degradation and hence leads to its
rapid accumulation in the cell [29]. Similarly, treatment of
cells with DFO (an inhibitor of propyl hydroxylases) also
causes cellular accumulation of the HIF-1α protein [26].
Herein, we found that pre-treatment of OVCAR-3 tumor
cells with ABZ inhibits hypoxia or DFO-induced HIF-1α
accumulation. More importantly, the present study
revealed that, in vivo administration of ABZ as a single
dose leads to profound suppression of tumoral HIF-1α
and VEGF.
It has been well established that solid tumor growth is
angiogenesis dependent and hypoxia is the major
pathophysiologic condition that regulates angiogenesis
[10]. Tumor hypoxia arises as a result of increased meta-
Figure 2 Suppression of tumoral HIF-1α by ABZ. Tumors harvested at various time-points from ABZ treated mice (single dose 150 mg/kg; i.p.) were 
examined by western blot analysis for the expression of HIF-1α protein (A) or by means of RT-PCR (B) and real time- PCR (C) for HIF-1α mRNA expres-
sion. Figures are representatives of protein and mRNA expression from the same tumor (6 mice per each treatment group).Pourgholami et al. BMC Cancer 2010, 10:143
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bolic activity and oxygen consumption by the rapidly pro-
liferating tumor cells. HIF-1α is a transcriptional
activator that mediates adaptive responses to hypoxia
through the induction of a number of growth factors and
cytokines [2,9]. In solid tumors, HIF-1α is a potent
inducer of VEGF which then plays a pivotal role in the
process of angiogenesis [30-32]. Based on this, targeting
tumoral HIF-1α is under intense investigation as a thera-
peutic strategy to inhibit angiogenesis and tumor growth.
In rapidly growing solid tumors reduced oxygen avail-
ability leads to inhibition of propyl hydroxylases, a dra-
matic surge in HIF-1α protein levels and consequently
induction of VEGF mRNA and protein [33]. Up-regula-
tion of VEGF leads to a series of events culminating in the
formation of new vessels to support the rapidly dividing
cells with the necessary oxygen and nutrients [9,34]. In
addition to up-regulation of VEGF expression, HIF-1α
itself has been found to be an important mediator of sur-
vival and angiogenesis and its over expression in the
majority of the human cancers has been associated with
patient mortality and poor response to treatment [35,36].
Based on this, targeting tumoral HIF-1α is under intense
investigation as a therapeutic target for cancer chemo-
therapy.
Furthermore, emerging experimental and clinical data
from VEGF-targeted therapies are suggesting develop-
ment of resistance and increased tumor invasiveness and
metastasis [6,12,37]. While it is entirely possible that the
resistance mechanisms are diverse and depend on tumor
type and the drug employed, up-regulation of several
well-defined signaling pathways such as placental growth
factor (PIGF), fibroblast growth factor (FGF), matrix
metalloproteinases (MMPs), notch and the HIF pathway
have been suggested [6,8]. In line with this, recent studies
have implicated the hypoxia/HIF-1α as an instigator of
invasion and metastasis [14,38,39]. Thus tumoral HIF-1α
inhibition is becoming an increasingly attractive thera-
peutic target in the treatment of cancer [40].
In this study we demonstrate for the first time that ABZ
is a potent inhibitor of HIF-1α under both in vitro and in
vivo  conditions. Under cell culture conditions, ABZ
inhibited hypoxia and DFO-induced accumulation of
HIF-1α.  In vivo, ABZ treatment led to diminished
tumoral HIF-1α levels. In line with this, tumoral VEGF
levels were also profoundly suppressed. Further trials are
needed to show if inhibition of the HIF-VEGF axis by
ABZ provides additional therapeutic benefit over agents
t h a t  o n l y  i n h i b i t  V E G F  o r  i t ' s  d o w n  s t r e a m  s i g n a l l i n g
pathways.
Conclusion
ABZ, a benzimidazole carbamate with extensive clinical
use as an anthelmintic, was shown in this study to be a
potent inhibitor of tumoral HIF-1α. Both VEGF and HIF-
1α are thought to be crucial mediators of angiogenesis
and tumor growth. Anti-VEGF agents may induce tumor
resistance. Inhibition of tumoral HIF-1α by ABZ may
thus prove to be advantageous in HIF induced anti-VEGF
resistance.
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